Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.89 |
| ▸ | HPGD | P15428 | 3/20 | 0.89 |
| ▸ | GAA | P10253 | 3/20 | 0.89 |
| ▸ | GLA | P06280 | 1/20 | 0.89 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7526429 | 0.88 | KDM4E (0.78) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL5452955 | 0.84 | ALDH1A1 (0.65) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL5440125 | 0.84 | HPGD (0.65) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL5439369 | 0.84 | ALDH1A1 (0.64) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL5440062 | 0.83 | KDM4E (0.64) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL5437071 | 0.83 | ALDH1A1 (0.64) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL5447101 | 0.83 | KDM4E (0.67) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL6314617 | 0.83 | KDM4E (0.67) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL5437131 | 0.82 | ALDH1A1 (0.62) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL5446562 | 0.82 | ALDH1A1 (0.62) | KDM4EALDH1A1HPGDGAAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946465-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2005-09-20 | — | — | US | claimed |
| US-20030236255-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2003-12-25 | — | — | US | claimed |
| US-20070043000-A1 | Immunosuppresive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2007-02-22 | — | — | US | disclosed |
| EP-1636232-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA Bioscience nv (BE) | 2006-03-22 | — | — | EP | disclosed |
| US-6946465-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2005-09-20 | — | — | US | disclosed |
| WO-2004104005-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2004-12-02 | — | — | WO | disclosed |
| EP-1479682-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA Bioscience nv (BE) | 2004-11-24 | — | — | EP | disclosed |
| US-20030236255-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2003-12-25 | — | — | US | disclosed |
| EP-1187615-A2 | IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | K.U. Leuven Research & Development (BE) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000045800-A2 | IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043000-A1 | Immunosuppresive effects of pteridine derivatives | TPMT, FKBP5, RRP15 | KDM4E 1686/4885ALDH1A1 1767/4885HPGD 1339/4885 |
| US-20030236255-A1 | Immunosuppressive effects of pteridine derivatives | TPMT, FKBP5, RRP15 | KDM4E 1278/4885ALDH1A1 1744/4885HPGD 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.